prostatepedia magazine covers

 

Prostatepedia features informal conversations with doctors, patients, and activists about prostate cancer about prostate cancer. Each month they tackle a different topic facing prostate cancer patients today—from how imaging has impacted treatment to dealing with erectile dysfunction after radiation or surgery to the evolving field of immunotherapy.

Prostatepedia Magazine (quarterly) and the weekly Prostatepedia Digests are now part of NASPCC, beginning with this month's August magazine issue.

Use this link to learn more about Prostatepedia...

NASPCC Presents THREE webinars in October/November:

“PSMA Imaging in Prostate Cancer: New Developments”

With Dr. Michael Morris, Clinical Director, Memorial Sloan-Kettering Cancer Center in New York

Thursday, October 1, 2020
7:00 pm – 8:00 pm Eastern

About the Presenter

dr michael morrisDr. Michael Morris is prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan-Kettering Cancer Center, where he was the Chief Fellow as well.

Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radio immunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.

In addition, he is the Medical Director of the Department of Prostate Cancer Clinical Consortium, and chairs the GU Committee of the Alliance for Oncology Trials in Oncology (formerly CALGB).

Registration

Use this link to register for the October 1st webinar>>

Sponsor

This Webinar is sponsored by: Progenics Pharmaceuticals

Progenics Pharmaceuticals: Find Fight and Follow 


“Immunotherapy and PARP Inhibition”

With Dr. Judd Moul, Professor, Duke University Medical Center.

Monday, October 5, 2020
7:00 pm – 8:00 pm Eastern.

About the Presenter

Judd Moul MDJudd W Moul, MD, FACS is the James H Semans MD Professor of Surgery at Duke University. In 2004, after completing a 26-year U.S. Army career and retiring as full Colonel in the Medical Corps, Moul became Chief of the Division of Urologic Surgery at Duke. Serving as Chief until 2011, he established the Duke Prostate Center (DPC) and directed the development of a DPC Outcomes database that contained the records of over 10,000 prostate cancer patients.

Dr. Moul serves on the editorial boards of American Journal of Men’s Health, Urology and Prostate Cancer and Prostatic Diseases. He serves on the Executive Committee for the American Joint Commission for Cancer (AJCC). Dr. Moul has published over 600 medical and scientific manuscripts and book chapters and has lectured at national and international meetings. He has been a visiting professor and invited guest lecturer at universities and national symposia, in addition to appearances on ABC, NBC, CNN, PBS, and other media as a prostate cancer authority. Honors and awards received have included the American Medical Association’s Young Physicians Section Community Service Award, the Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, the Gold Cystoscope Award by the American Urological Association, the Baron Dominique Jean Larrey Military Surgeon Award for Excellence, the Order of Military Medical Merit from the Surgeon General of the US Army, and the Castle Connolly National Physician of the Year award in 2009. *Dr. Judd Moul is not receiving any compensation for this presentation*

Registration

Please use this link to register for the October 5th webinar>>

 

Sponsor 

NASPCC is receiving support for this Webinar from:

Dendron: Targeting Cancer, Transforming Lives logo


“The PROCEED Registry and Disparities Work in Metastatic Prostate Cancer”

With Dr. Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research, the Duke Cancer Institute Center for Prostate and Urologic Cancers at Duke University.

Wednesday, November 4, 2020
7:00 pm – 8:00 pm Eastern.

About the Presenter

Andrew Armstrong MDDr. Andrew Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer, received his medical degree at the University of Virginia, medicine residency training at the University of Pennsylvania, fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health, and joined Duke’s faculty in 2006.

Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including completed or ongoing trials of AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and is heavily involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 170 peer reviewed publications as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovery science in GU cancers in the laboratory and treatment science in the clinic. As an R01 funded clinical-translational investigator, he has mentored over a dozen medical oncology fellows and junior faculty, and many residents and students both in the clinical, for clinical trials, and for laboratory training.

Registration

Please use this link to register for the November 4th webinar>>

Sponsor

NASPCC is receiving support for this Webinar from:

Dendron: Targeting Cancer, Transforming Lives logo

 

 

Please also check out our Archived Webinars...

Please use this link to view NASPCC's archived webinars...